<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hyporesponse to erythropoiesis-stimulating agents (ESAs) in chronic kidney disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey S Berns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas A Golper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric N Taylor, MD, MSc, FASN
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia associated with chronic kidney disease (CKD). ESA resistance, or hyporesponsiveness, is a term used to describe patients who do not achieve the desired hemoglobin (Hb) concentration despite higher than usual doses of ESAs or who require increasingly higher ESA doses to maintain an Hb concentration [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         ESA resistance is generally relative rather than complete, and, as such, ESA hyporesponsiveness is a more accurate description. This topic reviews ESA hyporesponsiveness in CKD patients. Recommendations for dosing and administration of ESAs in CKD and dialysis patients are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1952.html" rel="external">
          "Treatment of anemia in nondialysis chronic kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3332399465">
         <span class="h1">
          DEFINITION AND CRITERIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, ESA hyporesponsiveness is a term used to describe patients who do not achieve the desired hemoglobin (Hb) concentration despite higher than usual doses of ESAs or who require increasingly higher ESA doses to maintain a target Hb concentration [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Criteria for ESA hyporesponsiveness are not well defined. We use the Kidney Disease Outcomes Quality Initiative (KDOQI) criteria of inability to achieve or maintain a desired Hb concentration using a maximum dose of 450 units/kg per week intravenous erythropoietin or 300 units/kg per week subcutaneous erythropoietin [
         <a href="#rid2">
          2
         </a>
         ]. Criteria for other ESAs, such as
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin
         </a>
         and
         <a class="drug drug_general" data-topicid="101636" href="/z/d/drug information/101636.html" rel="external">
          methoxy polyethylene glycol-epoetin beta
         </a>
         , have not been defined, since precise dose conversions are not known. Package inserts suggest that 45,000 units/week of epoetin corresponds roughly to 100 mcg/week of darbepoetin.
        </p>
        <p>
         Other criteria have been suggested by European Best Practice Guidelines and Kidney Disease: Improving Global Outcomes (KDIGO) [
         <a href="#rid3">
          3,4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Failure to attain or maintain desired Hb concentration with 300 units/kg per week of erythropoietin (approximately 20,000 units/week) and 1.5 mcg/kg per week of
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin alfa
         </a>
         (approximately 100 mcg/week) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Having no increase in Hb concentration after the first month of appropriate weight-based dosing and/or requiring two increases in ESA doses up to 50 percent beyond the dose at which the patient had originally been stable [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         A practical definition of an ESA-resistant patient is one who requires a dose that is greater than that given to 90 percent of patients in a given facility.
        </p>
        <p class="headingAnchor" id="H3310194381">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         One contemporary, retrospective study identified ESA hyporesponsiveness, defined as two consecutive hemoglobin (Hb) levels &lt;10 g/dL while receiving epoetin &gt;7700 units per dose, in 12.5 percent of hemodialysis patients [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         ESA hyporesponsiveness among patients on peritoneal dialysis has not been well studied but is likely much less common than among hemodialysis patients as peritoneal dialysis patients generally tend to have higher Hb levels and require lower ESA doses [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2248685631">
         <span class="h1">
          CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron deficiency and infection and/or inflammation are the two most common causes of ESA hyporesponsiveness. These and other causes are discussed below.
        </p>
        <p class="headingAnchor" id="H195055808">
         <span class="h2">
          Iron deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Iron deficiency is a common cause of ESA hyporesponsiveness. Iron deficiency may be absolute (which is often due to external blood losses) or functional (related to ESA administration or anemia of chronic disease). All patients with ESA hyporesponsiveness should be assessed for absolute and functional iron deficiency. (See
         <a class="medical medical_review" href="/z/d/html/1951.html" rel="external">
          "Diagnosis of iron deficiency in chronic kidney disease", section on 'Definitions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1189184299">
         <span class="h2">
          Infection or inflammation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic inflammation is common among hemodialysis patients and an important cause of ESA hyporesponsiveness [
         <a href="#rid8">
          8-12
         </a>
         ]. Dialysis catheters are a common cause of chronic inflammation. Other causes include skin or wound infections; failed kidney transplant; and occult infection of an old, nonfunctioning arteriovenous graft [
         <a href="#rid10">
          10-13
         </a>
         ]. The role of hepatitis C as a cause of ESA hyporesponsiveness has not been studied. (See
         <a class="medical medical_review" href="/z/d/html/1939.html" rel="external">
          "Inflammation in patients with kidney function impairment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7149.html" rel="external">
          "Anemia of chronic disease/anemia of inflammation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7320.html" rel="external">
          "Kidney transplantation in adults: Management of the patient with a failed kidney transplant"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H112719415">
         <span class="h2">
          Inadequate dialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inadequate dialysis may cause ESA hyporesponsiveness [
         <a href="#rid14">
          14,15
         </a>
         ]. In an old study of 20 stable hemodialysis patients who were modestly under-dialyzed (mean urea reduction ratio [URR] 60.7 percent), increasing the dialysis dose was associated with an increase in hematocrit despite a constant dose of ESA [
         <a href="#rid14">
          14
         </a>
         ]. Differences in the dialysis membrane may have affected the ESA response since the increase in urea clearance was achieved by changing to a larger dialyzer with a different membrane. However, the dialyzer membrane has not been shown to affect the ESA response in other studies [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p>
         An increase in the dialysis dose is unlikely to increase ESA response in patients who are already being adequately dialyzed (ie, single-pool Kt/V ≥1.0 to 1.2) [
         <a href="#rid14">
          14,19,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">
          "Prescribing and assessing adequate hemodialysis", section on 'Target Kt/V'
         </a>
         .)
        </p>
        <p>
         Changes in the dialysis modality also may affect ESA responsiveness [
         <a href="#rid6">
          6,7
         </a>
         ]. The effect of short daily and long nocturnal hemodialysis on anemia and ESA response is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1959.html" rel="external">
          "Outcomes associated with nocturnal hemodialysis", section on 'Anemia'
         </a>
         .)
        </p>
        <p>
         Use of ultrapure dialysate has been associated with improved hemoglobin (Hb) concentrations and reduced ESA requirements [
         <a href="#rid21">
          21-23
         </a>
         ]. This association is believed to be related to reduced inflammation. Ultrapure dialysate is dialysate that is of much higher microbiologic purity than is required by some international and national standards. (See
         <a class="medical medical_review" href="/z/d/html/1948.html" rel="external">
          "Ultrapure dialysis fluid", section on 'Potential clinical benefits of ultrapure dialysis fluid'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H727180751">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other conditions associated with ESA hyporesponsiveness include severe hyperparathyroidism with osteitis fibrosis cystica, malignancy, bone marrow disorders such as myelodysplastic syndrome and multiple myeloma, and hemoglobinopathies, such as sickle cell disease. B12 and folate deficiencies have also been reported in ESA hyporesponsive patients [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Pure red cell aplasia, a condition of complete ESA hyporesponsiveness, has been associated with the subcutaneous administration of a particular brand of ESA, which is no longer available. (See
         <a class="medical medical_review" href="/z/d/html/1930.html" rel="external">
          "Pure red cell aplasia (PRCA) due to anti-erythropoiesis-stimulating agent antibodies"
         </a>
         .)
        </p>
        <p>
         Some reports suggest that the administration of angiotensin-converting enzyme (ACE) inhibitors and/or angiotensin II receptor antagonists may cause relative ESA hyporesponsiveness, but this does not seem to be clinically important or common [
         <a href="#rid25">
          25-27
         </a>
         ]. This effect may have genetic determinants [
         <a href="#rid28">
          28
         </a>
         ]. Possible mechanisms of ESA hyporesponsiveness in this setting are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7348.html" rel="external">
          "Kidney transplantation in adults: Posttransplant erythrocytosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H316700478">
         <span class="h1">
          OUR APPROACH TO ESA HYPORESPONSIVENESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is important to carefully evaluate erythropoiesis-stimulating agent (ESA)-resistant patients. ESA hyporesponsiveness is associated with increased mortality, and many causes of ESA hyporesponsiveness can be addressed. Our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We exclude both absolute and functional iron deficiency and treat with iron, if present. Even in the absence of documented absolute iron deficiency, some patients will have an increase in hemoglobin concentration with additional iron supplementation given intravenously. (See
         <a class="medical medical_review" href="/z/d/html/1953.html" rel="external">
          "Treatment of iron deficiency in patients on dialysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1943.html" rel="external">
          "Treatment of iron deficiency in patients with nondialysis chronic kidney disease (CKD)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We make sure patients are adequately dialyzed. Among patients who are not achieving the minimum Kt/V, we modify the dialysis prescription to increase the amount of delivered dialysis. (See
         <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">
          "Prescribing and assessing adequate hemodialysis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">
          "Prescribing peritoneal dialysis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We perform a careful physical exam to exclude occult infection, with particular attention to thrombosed arteriovenous grafts. (See
         <a class="medical medical_review" href="/z/d/html/89537.html" rel="external">
          "Physical examination of the arteriovenous graft", section on 'Detection of specific problems'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Observational studies suggest that removal of old grafts is associated with improved ESA responsiveness [
         <a href="#rid11">
          11
         </a>
         ]. Among those with a hemodialysis catheter, placement of arteriovenous access and removal of the catheter may also improve ESA responsiveness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with severe hyperparathyroidism, we attempt to restore optimal parathyroid hormone (PTH) concentrations with pharmacologic therapy or parathyroidectomy. Treatment of hyperparathyroidism improves ESA response [
         <a href="#rid29">
          29-31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">
          "Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         For patients on dialysis with an unknown or untreatable cause of ESA hyporesponsiveness, a trial of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF PHI) therapy is reasonable. We do not use HIF PHIs in patients with nondialysis CKD. Data supporting the efficacy of HIF PHI therapy in patients with ESA hyporesponsiveness are sparse [
         <a href="#rid32">
          32,33
         </a>
         ]; additional studies are needed to assess the role of HIF PHIs in this setting. Our approach to the use of HIF PHIs is detailed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1926.html" rel="external">
          "Treatment of anemia in patients on dialysis", section on 'Choice of therapy in iron replete patients'
         </a>
         .)
        </p>
        <p>
         In patients with ESA hyporesponsiveness, the ESA can be stopped or continued at a low dose that helps to minimize transfusion requirements with use of transfusions as needed to manage anemia-related symptoms [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2402784280">
         <span class="h1">
          OUTCOMES
         </span>
        </p>
        <p class="headingAnchor" id="H2240738513">
         <span class="h2">
          Mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         ESA hyporesponsiveness is associated with increased mortality [
         <a href="#rid35">
          35-37
         </a>
         ]. In one observational study of hemodialysis patients in the United States, patients who had hemoglobin (Hb) &lt;9.5 g/dL and received larger ESA dose changes over an 11-month period had a higher mortality risk (hazard ratio [HR] 1.32) [
         <a href="#rid35">
          35
         </a>
         ]. In another study that used data from the Normal Hematocrit Cardiac Trial, a higher erythropoietin-responsiveness measure (defined as the ratio of the weekly hematocrit change per ESA dose increase) was associated with lower mortality (with an adjusted HR of 0.41 for highest versus lowest quartiles) [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         The effect of ESA hyporesponsiveness on mortality among peritoneal dialysis patients has not been well studied. One study from Korea suggested that ESA hyporesponsiveness was associated with higher mortality among hemodialysis patients but not peritoneal dialysis patients [
         <a href="#rid38">
          38
         </a>
         ]. However, other studies that have compared hemodialysis and peritoneal dialysis have not found such an association [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
         The increased mortality associated with ESA hyporesponsiveness is likely due to the underlying cause of ESA hyporesponsiveness. However, some studies have suggested that the increased mortality is related to the higher ESA doses that are used in these patients [
         <a href="#rid37">
          37,41-47
         </a>
         ]. As an example, in an unadjusted analysis of the Correction of Hemoglobin in the Outcomes in Renal Insufficiency (CHOIR) trial, an increased risk of the primary composite endpoint (death, myocardial infarction, heart failure, or stroke) at four months was associated with both an inability to achieve target levels and higher doses of epoetin (&gt;20,000 units per week) [
         <a href="#rid46">
          46
         </a>
         ]. However, adjusted analysis found that
         <strong>
          only
         </strong>
         high-dose epoetin therapy resulted in an independent increased risk of the primary composite endpoint (HR 1.57, 95% CI 1.04-2.36). This increased risk was observed in both high- and low-target Hb groups, particularly among those unable to reach target Hb levels.
        </p>
        <p>
         While most studies have focused on hyporesponsiveness during ongoing chronic ESA treatment, the relationship between initial Hb response to
         <a class="drug drug_general" data-topicid="8662" href="/z/d/drug information/8662.html" rel="external">
          darbepoetin
         </a>
         was assessed in the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study [
         <a href="#rid37">
          37
         </a>
         ]. Patients who did not respond to the initial two doses of darbepoetin had higher rates of a composite cardiovascular endpoint and death compared with those with a better initial treatment response.
        </p>
        <p>
         In addition, a meta-regression analysis of 31 trials (12,956 patients) found that all-cause mortality was associated with higher first three-month and total-study-period mean ESA dose independent of Hb level [
         <a href="#rid48">
          48,49
         </a>
         ]. There was a similar trend for cardiovascular mortality that was not statistically significant. Higher total-study-period mean ESA dose also was associated with an increased rate of hypertension, stroke, and thrombotic events, including dialysis vascular access-related thrombotic events.
        </p>
        <p>
         However the association between higher ESA doses and mortality has not been shown in all studies. In one observational study of older hemodialysis patients, doses of epoetin that exceeded 30,000 units per week were not associated with harm or benefit [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4015848632">
         <span class="h2">
          Progression of chronic kidney disease (CKD)
         </span>
         <span class="headingEndMark">
          —
         </span>
         ESA hyporesponsiveness may be associated with more rapid progression to end-stage kidney disease (ESKD) [
         <a href="#rid51">
          51
         </a>
         ]. This was suggested by a study of 194 consecutive CKD patients who started ESAs between 2002 and 2006 [
         <a href="#rid52">
          52
         </a>
         ]. Patients were classified as poor, intermediate, and good responders based upon their response to the first administered ESA dose. Responsiveness was calculated according to the formula: (Hb
         <sub>
          1
         </sub>
         -Hb
         <sub>
          0
         </sub>
         )/time/ESA dose where Hb
         <sub>
          1
         </sub>
         and Hb
         <sub>
          0
         </sub>
         correspond to Hb values at the first visit after ESA administration and at baseline, respectively; time refers to the period between visits; and ESA dose is the first weekly dose prescribed. ESA responsiveness was expressed as g/dL/month, standardized to 10 mcg/week. During a median follow-up of three years, poor responsiveness was associated with a higher risk of ESKD (HR 2.49, 95% CI 1.28-4.84). The mechanism underlying this possible association is not known.
        </p>
        <p class="headingAnchor" id="H509797699">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111938.html" rel="external">
          "Society guideline links: Anemia in chronic kidney disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition and criteria
         </strong>
         – Erythropoiesis-stimulating agents (ESAs) are commonly used to treat anemia associated with chronic kidney disease (CKD). Patients who do not achieve the desired hemoglobin (Hb) concentration despite higher than usual ESA doses or who require increasingly higher ESA doses to maintain an Hb concentration are considered ESA resistant. Criteria for ESA hyporesponsiveness are not well defined. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Definition and criteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes
         </strong>
         – Causes of ESA hyporesponsiveness include absolute and functional iron deficiency, infection or inflammation, inadequate dialysis, severe hyperparathyroidism (with osteitis fibrosa cystica), and malignancy or hematologic disorders. (See
         <a class="local">
          'Causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to ESA hyporesponsiveness
         </strong>
         – It is important to carefully evaluate ESA-resistant patients for potential causes. Our approach is as follows (see
         <a class="local">
          'Our approach to ESA hyporesponsiveness'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We exclude both absolute and functional iron deficiency and treat with iron, if present.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We make sure patients are adequately dialyzed. Among patients who are not achieving the minimum Kt/V, we modify the dialysis prescription to increase the amount of delivered dialysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We perform a careful physical exam to exclude occult infection, with particular attention to thrombosed arteriovenous grafts.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Among patients with severe hyperparathyroidism, we attempt to restore optimal parathyroid hormone (PTH) concentrations with pharmacologic therapy or parathyroidectomy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – ESA hyporesponsiveness has been associated with increased mortality among both patients on hemodialysis and those on peritoneal dialysis, as well as patients with CKD who are not on dialysis. This is likely due to the underlying cause of ESA hyporesponsiveness, although higher ESA doses used in these patients may also contribute to higher risk of adverse events including death. (See
         <a class="local">
          'Outcomes'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sibbel SP, Koro CE, Brunelli SM, Cobitz AR. Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients. BMC Nephrol 2015; 16:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001; 37:S182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapter 1: Diagnosis and evaluation of anemia in CKD. Kidney Int Suppl (2011) 2012; 2:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 Suppl 2:ii1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luo J, Jensen DE, Maroni BJ, Brunelli SM. Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients. Am J Kidney Dis 2016; 68:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besarab A, Golper TA. Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients. ASAIO Trans 1991; 37:M395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golper TA. The effect of recombinant erythropoietin on the early hematocrit rise after CAPD initiation. Perit Dial Int 1992; 12:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 1998; 54:1337.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 1999; 33:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Gómez JM, Pérez-Flores I, Jofré R, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15:2494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nassar GM, Fishbane S, Ayus JC. Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int Suppl 2002; :49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts TL, Obrador GT, St Peter WL, et al. Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. Kidney Int 2004; 66:2429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solid CA, Foley RN, Gill JS, et al. Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants. Kidney Int 2007; 71:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 1996; 334:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Movilli E, Cancarini GC, Zani R, et al. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients. Nephrol Dial Transplant 2001; 16:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant 2000; 15:1399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Opatrný K Jr, Reischig T, Vienken J, et al. Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis. Artif Organs 2002; 26:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richardson D, Lindley EJ, Bartlett C, Will EJ. A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response. Am J Kidney Dis 2003; 42:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locatelli F, Del Vecchio L. Dialysis adequacy and response to erythropoietic agents: what is the evidence base? Nephrol Dial Transplant 2003; 18 Suppl 8:viii29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Movilli E, Cancarini GC, Vizzardi V, et al. Epoetin requirement does not depend on dialysis dose when Kt/N &gt; 1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores. J Nephrol 2003; 16:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu PY, Lin CL, Yu CC, et al. Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study. J Nephrol 2004; 17:693.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffl H, Lang SM, Bergner A. Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999; 83:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15:1207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology (Carlton) 2007; 12:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albitar S, Genin R, Fen-Chong M, et al. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol Dial Transplant 1998; 13:1206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwarzbeck A, Wittenmeier KW, Hällfritzsch U. Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ertürk S, Nergizoğlu G, Ateş K, et al. The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients. Nephrol Dial Transplant 1999; 14:1912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiss Z, Ambrus C, Kulcsár I, et al. Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis. J Renin Angiotensin Aldosterone Syst 2015; 16:1021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin CL, Hung CC, Yang CT, Huang CC. Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients. Ren Fail 2004; 26:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rault R, Magnone M. The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis. ASAIO J 1996; 42:M901.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Battistella M, Richardson RM, Bargman JM, Chan CT. Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease. Clin Nephrol 2011; 76:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cizman B, Sykes AP, Paul G, et al. An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. Kidney Int Rep 2018; 3:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu WH, Li XJ, Yuan F. Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report. World J Clin Cases 2020; 8:6048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karaboyas A, Morgenstern H, Fleischer NL, et al. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Med 2020; 2:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol 2009; 4:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kilpatrick RD, Critchlow CW, Fishbane S, et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363:1146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bae MN, Kim SH, Kim YO, et al. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients. PLoS One 2015; 10:e0143348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duong U, Kalantar-Zadeh K, Molnar MZ, et al. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol 2012; 35:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suttorp MM, Hoekstra T, Rotmans JI, et al. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol 2013; 14:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ofsthun N, Labrecque J, Lacson E, et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int 2003; 63:1908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts TL, Foley RN, Weinhandl ED, et al. Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrol Dial Transplant 2006; 21:1652.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradbury BD, Wang O, Critchlow CW, et al. Exploring relative mortality and epoetin alfa dose among hemodialysis patients. Am J Kidney Dis 2008; 51:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007; 2:1274.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szczech LA, Barnhart HX, Inrig JK, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AK. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro. J Am Soc Nephrol 2009; 20:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013; 61:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaknos CM, Berns JS. Erythropoiesis-stimulating agents on trial: are higher dosages causing harm? Am J Kidney Dis 2013; 61:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Thamer M, Cotter D, et al. Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States. Clin J Am Soc Nephrol 2009; 4:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimura H, Sy J, Okuda Y, et al. A faster decline of residual kidney function and erythropoietin stimulating agent hyporesponsiveness in incident hemodialysis patients. Hemodial Int 2021; 25:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minutolo R, Conte G, Cianciaruso B, et al. Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients. Nephrol Dial Transplant 2012; 27:2880.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1935 Version 40.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26283069" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11229970" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25018948" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Chapter 1: Diagnosis and evaluation of anemia in CKD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15206425" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27528373" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1751205" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Response of continuous peritoneal dialysis patients to subcutaneous recombinant human erythropoietin differs from that of hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1543778" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The effect of recombinant erythropoietin on the early hematocrit rise after CAPD initiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9767553" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Role of cytokines in the response to erythropoietin in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9915269" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15340000" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11982813" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Occult infection of old nonfunctioning arteriovenous grafts: a novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15569336" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17213875" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8552143" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11209002" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10978398" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effect of high-flux dialysis on the anaemia of haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11879248" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Does treatment modality have an impact on anemia in patients with chronic renal failure? Effect of low- and high-flux biocompatible dialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12955684" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A randomized, controlled study of the consequences of hemodialysis membrane composition on erythropoietic response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14607998" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Dialysis adequacy and response to erythropoietic agents: what is the evidence base?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14696757" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Epoetin requirement does not depend on dialysis dose when Kt/N&gt;1.33 in patients on regular dialysis treatment with cellulosic membranes and adequate iron stores.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15593037" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients - a prospective cross-over study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10529639" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ultrapure dialysate reduces dose of recombinant human erythropoietin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10910446" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17635745" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Erythropoiesis-stimulating agent hyporesponsiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9623555" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9690412" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Anaemia in dialysis patients as a side-effect of sartanes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10462270" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The impact of withdrawing ACE inhibitors on erythropoietin responsiveness and left ventricular hypertrophy in haemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25002133" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15354979" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Improved anemia and reduced erythropoietin need by medical or surgical intervention of secondary hyperparathyroidism in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8945016" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21762640" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29989040" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33344604" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Roxadustat for treatment of erythropoietin-hyporesponsive anemia in a hemodialysis patient: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32734248" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19261826" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18417744" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20843249" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Erythropoietic response and outcomes in kidney disease and type 2 diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26588085" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22286821" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24066978" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12675871" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9718377" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16449283" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Anaemia and mortality in haemodialysis patients: interaction of propensity score for predicted anaemia and actual haemoglobin levels.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18155534" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Exploring relative mortality and epoetin alfa dose among hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17942772" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18596733" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19579295" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: pro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22921639" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23245737" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Erythropoiesis-stimulating agents on trial: are higher dosages causing harm?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19261818" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33034069" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A faster decline of residual kidney function and erythropoietin stimulating agent hyporesponsiveness in incident hemodialysis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22319218" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
